CNTB

CNTB

Connect Biopharma Holdings Ltd

Rev —top 1%5Y
Hold

Connect Biopharma Holdings Limited develops therapies for inflammatory diseases, focusing on rademikibart, an antibody targeting interleukin-4 receptor alpha. It's in Phase 3 trials for conditions like asthma and atopic dermatitis in the U.S. market.

⚕️ Healthcare NASDAQ Listed 2021 ¥ CNY
$1,000 invested 5 years ago $92today

Score Overview

1 Year
Score
Net Growth-16.45%
Net TrendShrank
Net Income Consistency
Rev Growth289.06%
Rev TrendGrew
Revenue Consistency
5 Years
Score
Net Growth68.06%
Net Trend60%
Net Income Consistency
Rev Growth
Rev Trend40%
Revenue Consistency
All Time
Score
Net Growth68.06%
Net Trend60%
Net Income Consistency
Rev Growth
Rev Trend40%
Revenue Consistency

See the full market ranking →

Connect Biopharma Holdings Ltd fundamental performance

Across Connect Biopharma Holdings Ltd's full reported history, from 2021 to 2025, revenue grew from ¥ 0.00 to ¥ 64K and net income went from -¥ 202M to -¥ 55M. Revenue increased in 40% of the years measured; net income in 60%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 2.33
1 Year2025-08-12
$ 2.272.64%
5 Years2021-08-12
$ 25.25-90.77%
All Time2021-03-19
$ 18.49-87.40%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026¥ 249K-¥ 64M
2025¥ 64K-¥ 55M¥ 44M
2024¥ 26M-¥ 15M¥ 93M
2023¥ 0.00-¥ 62M¥ 118M
2022¥ 0.00-¥ 118M¥ 152M
IPO2021¥ 0.00-¥ 202M¥ 267M

Explore beyond CNTB

You're looking at Connect Biopharma Holdings Ltd. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies